Literature DB >> 8111822

Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter.

J K Andersen1, D M Frim, O Isacson, X O Breakefield.   

Abstract

1. Herpesvirus infection with genetically engineered vectors is a way to deliver foreign gene products to various cell populations in culture and in vivo. Selective neuronal gene expression can be achieved using the neuron-specific enolase (NSE) promoter regulating expression of a transgene placed in and delivered by a herpesvirus vector. 2. We sought to determine the anatomical specificity and efficiency of herpesvirus-mediated gene transfer into the rat brain following placement of virus particles carrying a transgene (lacZ) under control of the NSE promoter. The virus utilized was thymidine kinase (TK) deficient and therefore replication deficient in the brain. 3. Infusion of 10(6) plaque-forming units of virus into the striatum caused a limited number of striatal neurons to express the lacZ transgene mRNA and protein product 7 days postinfection. In addition, small numbers of neurons expressing the transgene mRNA and protein were found ipsilateral to the viral injection in the frontal cortex, substantia nigra pars compacta, and thalamus. Neurons at these anatomic loci project directly to the striatal injection site. No other cells within the brains of injected animals expressed the lacZ gene. 4. While this herpesvirus NSE vector was capable of introducing novel functional genetic information into postmitotic neurons within defined neuroanatomic constraints, the numbers of neurons expressing detectable levels of beta-galactosidase was minimal. The calculated efficiency of delivery and transgene expression at 7 days postinfection was 1 transgenic neuron per 10(4) virus particles infused. 5. We conclude that NSE probably is not an optimal promoter for use in gene delivery to CNS neurons in herpesvirus vectors and that the efficacy of gene delivery using other neuron-specific promoters placed at various sites in the herpes viral genome needs to be explored.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8111822     DOI: 10.1007/bf00711459

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  43 in total

1.  Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome.

Authors:  R L Thompson; S K Rogers; M A Zerhusen
Journal:  Virology       Date:  1989-10       Impact factor: 3.616

2.  Autologous fibroblast implantation. Feasibility and potential problems in gene replacement therapy.

Authors:  P L Chang; J P Capone; G M Brown
Journal:  Mol Biol Med       Date:  1990-12

3.  A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

Authors:  A T Dobson; T P Margolis; F Sedarati; J G Stevens; L T Feldman
Journal:  Neuron       Date:  1990-09       Impact factor: 17.173

4.  Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control.

Authors:  S Forss-Petter; P E Danielson; S Catsicas; E Battenberg; J Price; M Nerenberg; J G Sutcliffe
Journal:  Neuron       Date:  1990-08       Impact factor: 17.173

5.  Combining CNS transplantation and gene transfer.

Authors:  X O Breakefield
Journal:  Neurobiol Aging       Date:  1989 Sep-Oct       Impact factor: 4.673

6.  A model system for in vivo gene transfer into the central nervous system using an adenoviral vector.

Authors:  B L Davidson; E D Allen; K F Kozarsky; J M Wilson; B J Roessler
Journal:  Nat Genet       Date:  1993-03       Impact factor: 38.330

7.  Gene therapy in the CNS: intracerebral grafting of genetically modified cells.

Authors:  F H Gage; M B Rosenberg; M H Tuszynski; K Yoshida; D M Armstrong; R C Hayes; T Friedmann
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

8.  Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter.

Authors:  J K Andersen; D A Garber; C A Meaney; X O Breakefield
Journal:  Hum Gene Ther       Date:  1992-10       Impact factor: 5.695

9.  Localization of a herpes simplex virus neurovirulence gene dissociated from high-titer virus replication in the brain.

Authors:  R T Javier; K M Izumi; J G Stevens
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression.

Authors:  M B Rosenberg; T Friedmann; R C Robertson; M Tuszynski; J A Wolff; X O Breakefield; F H Gage
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

View more
  6 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Atomic structure of the human cytomegalovirus capsid with its securing tegument layer of pp150.

Authors:  Xuekui Yu; Jonathan Jih; Jiansen Jiang; Z Hong Zhou
Journal:  Science       Date:  2017-06-30       Impact factor: 47.728

4.  Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.

Authors:  Y Han; Q A Chang; T Virag; N C West; D George; M G Castro; M C Bohn
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

5.  Noninvasive in vivo monitoring of neuronal differentiation using reporter driven by a neuronal promoter.

Authors:  Do Won Hwang; Joo Hyun Kang; Jae Min Jeong; June-Key Chung; Myung Chul Lee; Soonhag Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

6.  Characterization of neural stem cells modified with hypoxia/neuron-specific VEGF expression system for spinal cord injury.

Authors:  Y Yun; J Oh; Y Kim; G Kim; M Lee; Y Ha
Journal:  Gene Ther       Date:  2017-11-20       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.